Regulus Therapeutics (RGLS) Tops Q1 EPS by 10c

Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.15), $0.10 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Obsidian Energy Increases Syndicated Credit Facility
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook